Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Sees Large Drop in Short Interest

Key Points

• Daiichi Sankyo Co., Ltd. experienced a 66.7% decrease in short interest in September, dropping from 101,000 shares to 33,600 shares.
• The company's stock price rose to $24.30, with a market capitalization of $46.02 billion and a price-to-earnings ratio of 22.92.
• Wall Street analysts have rated Daiichi Sankyo as a "strong-buy," reflecting optimism about the company's future growth.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 33,600 shares, a decrease of 66.7% from the August 31st total of 101,000 shares. Based on an average daily trading volume, of 340,700 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily trading volume, of 340,700 shares, the days-to-cover ratio is currently 0.1 days.

Daiichi Sankyo Stock Performance

OTCMKTS:DSNKY traded up $1.05 during mid-day trading on Thursday, hitting $24.30. 281,079 shares of the company's stock traded hands, compared to its average volume of 255,954. The firm has a 50 day moving average of $24.32 and a two-hundred day moving average of $24.17. Daiichi Sankyo has a 12 month low of $20.92 and a 12 month high of $34.19. The firm has a market capitalization of $46.02 billion and a price-to-earnings ratio of 22.92. The company has a current ratio of 2.31, a quick ratio of 1.60 and a debt-to-equity ratio of 0.06.

Wall Street Analysts Forecast Growth

Separately, Nomura Securities raised Daiichi Sankyo to a "strong-buy" rating in a report on Friday, June 6th. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock has an average rating of "Strong Buy".

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.